Table 1.
Patient background information.
| N = 20 | |
|---|---|
| Age, years | 62.0 ± 6.9 |
| Sex (female), n (%) | 8 (40.0) |
| Disease duration, years | 1.9 (0.4, 4.8) |
| Initial symptom, n (%) | |
| Bulbar onset | 5 (25.0) |
| Limb onset | 14 (70.0) |
| Respiratory failure | 1 (5.0) |
| ALSFRS-R score | 38.4 ± 6.5 |
| Body weight, kg | 59.7 ± 12.5 |
| Body mass index, kg/m2 | 22.3 ± 3.4 |
| Soft lean mass, kg | 40.1 ± 10.0 |
| Body fat mass, kg | 17.0 ± 5.0 |
| MNA score | 23.1 ± 4.5 |
| mRMR, kcal | 1294 ± 221 |
| TEE, kcal | 1934 ± 396 |
| Plasma amino acids (arginine), nmol/ml | 73.2 ± 17.4 |
| Urine amino acids (arginine), µmol/g・cre | 20.0 ± 15.3 |
| Concomitant use of riluzole, n (%) | 15 (75.0) |
| Concomitant use of edaravone, n (%) | 6 (30.0) |
| PEG, n (%) | 1 (5.0) |
| NPPV, n (%) | 1 (5.0) |
ALSFRS-R, revised ALS functional rating scale; MNA, mini nutritional assessment; mRMR, measured resting metabolic rate; TEE, total energy expenditure; PEG, percutaneous endoscopic gastrostomy; NPPV, noninvasive positive pressure ventilation.
The data are expressed as the mean ± standard deviation or median (minimum, maximum) for continuous variables and as frequencies and percentages for discrete variables.